Swedencare AB (publ) (SECARE.ST)
SEK 48.8
(-2.4%)
SEK 48.8
(-2.4%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.12 Billion SEK | 24.8% |
| 2022 | 895.48 Million SEK | 176.42% |
| 2021 | 323.96 Million SEK | 232.88% |
| 2020 | 97.32 Million SEK | 71.73% |
| 2019 | 56.67 Million SEK | 28.77% |
| 2018 | 44 Million SEK | -6.45% |
| 2017 | 47.04 Million SEK | 50.85% |
| 2016 | 31.18 Million SEK | 25.64% |
| 2015 | 24.82 Million SEK | 138.95% |
| 2014 | 10.38 Million SEK | -3.17% |
| 2013 | 10.72 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 306.2 Million SEK | 7.74% |
| 2024 Q1 | 284.2 Million SEK | -8.85% |
| 2024 Q3 | 314.6 Million SEK | 2.74% |
| 2023 Q1 | 255.5 Million SEK | 1.89% |
| 2023 FY | 1.11 Billion SEK | 24.8% |
| 2023 Q2 | 274.1 Million SEK | 7.28% |
| 2023 Q3 | 276.3 Million SEK | 0.8% |
| 2023 Q4 | 311.8 Million SEK | 12.85% |
| 2022 Q1 | 179.64 Million SEK | 29.07% |
| 2022 FY | 895.48 Million SEK | 176.42% |
| 2022 Q3 | 234.91 Million SEK | 3.78% |
| 2022 Q4 | 250.75 Million SEK | 6.74% |
| 2022 Q2 | 226.36 Million SEK | 26.01% |
| 2021 Q2 | 50.27 Million SEK | 10.6% |
| 2021 Q3 | 89.05 Million SEK | 77.13% |
| 2021 Q4 | 139.18 Million SEK | 56.29% |
| 2021 Q1 | 45.45 Million SEK | 17.26% |
| 2021 FY | 323.96 Million SEK | 232.88% |
| 2020 Q3 | 24 Million SEK | 40.14% |
| 2020 Q2 | 17.13 Million SEK | 5.18% |
| 2020 FY | 97.32 Million SEK | 71.73% |
| 2020 Q4 | 38.76 Million SEK | 61.46% |
| 2020 Q1 | 16.28 Million SEK | -11.74% |
| 2019 Q3 | 12.41 Million SEK | -5.96% |
| 2019 Q2 | 13.19 Million SEK | 4.7% |
| 2019 Q1 | 12.6 Million SEK | -4.87% |
| 2019 FY | 56.67 Million SEK | 28.77% |
| 2019 Q4 | 18.45 Million SEK | 48.69% |
| 2018 Q1 | 9.9 Million SEK | -14.74% |
| 2018 Q3 | 9.72 Million SEK | -12.61% |
| 2018 Q4 | 13.25 Million SEK | 36.28% |
| 2018 FY | 44 Million SEK | -6.45% |
| 2018 Q2 | 11.12 Million SEK | 12.33% |
| 2017 Q3 | 12.22 Million SEK | -0.15% |
| 2017 Q4 | 11.61 Million SEK | -4.93% |
| 2017 FY | 47.04 Million SEK | 50.85% |
| 2017 Q1 | 10.96 Million SEK | 5.87% |
| 2017 Q2 | 12.24 Million SEK | 11.68% |
| 2016 Q1 | 7.22 Million SEK | -61.79% |
| 2016 Q4 | 10.35 Million SEK | 45.15% |
| 2016 Q3 | 7.13 Million SEK | 13.86% |
| 2016 Q2 | 6.26 Million SEK | -13.24% |
| 2016 FY | 31.18 Million SEK | 25.64% |
| 2015 Q1 | 1.8 Million SEK | 0.0% |
| 2015 FY | 24.82 Million SEK | 138.95% |
| 2015 Q4 | 18.89 Million SEK | 744.7% |
| 2015 Q2 | 1.89 Million SEK | 4.82% |
| 2015 Q3 | 2.23 Million SEK | 18.23% |
| 2014 FY | 10.38 Million SEK | -3.17% |
| 2013 FY | 10.72 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AcuCort AB | 13.24 Million SEK | -8412.341% |
| AlzeCure Pharma AB (publ) | 38.26 Million SEK | -2847.572% |
| BioGaia AB (publ) | 507.08 Million SEK | -122.408% |
| Enzymatica AB (publ) | 79.92 Million SEK | -1311.073% |
| Enorama Pharma AB (publ) | 38.22 Million SEK | -2850.348% |
| Gabather AB (publ) | 9.47 Million SEK | -11804.159% |
| Klaria Pharma Holding AB (publ.) | 14.88 Million SEK | -7477.264% |
| Moberg Pharma AB (publ) | 27.46 Million SEK | -4006.616% |
| Nanexa AB (publ) | 135.78 Million SEK | -730.596% |
| Newbury Pharmaceuticals AB (publ) | 30.11 Million SEK | -3645.475% |
| ODI Pharma AB | -5.00 SEK | 22556000100.0% |
| Orexo AB (publ) | 659.4 Million SEK | -71.034% |
| Probi AB (publ) | 208.93 Million SEK | -439.79% |
| Swedish Orphan Biovitrum AB (publ) | 9.39 Billion SEK | 87.998% |
| Toleranzia AB | 6.97 Million SEK | -16076.133% |
| Vivesto AB | 355.71 Million SEK | -217.049% |